Chugai Pharmaceutical Co., Ltd. Initiates Clinical Trials for Multiple In-Licensed Compounds in Cooperation with Roche Holding Ltd

Chugai Pharmaceutical Co., Ltd. announced that it has entered into license agreements with Roche Holding Ltd covering humanized anti-Met antibody MetMAb, for non-small cell lung cancer (NSCLC) and humanized anti-interleukin(IL)-13 antibody lebrikizumab for bronchial asthma which are both currently developed by Roche utilizing the Personalized Healthcare (PHC) approach and have also entered phase I clinical studies in the Japanese population. Under the agreement, Chugai obtains rights for the development and marketing of these compounds in Japan, and will make milestone payments to Roche.